Single-dose versus multiple-dose HPV vaccination for prevention of cervical cancer: a systematic review and meta-analysis
DOI:
https://doi.org/10.18203/2320-6012.ijrms20262192Keywords:
Vaccine effectiveness, Meta-analysis, Cervical cancer prevention, Multiple-dose, HPV vaccination, Single-doseAbstract
Cervical cancer remains a major global burden, especially in low- and middle-income countries (LMICs). Although HPV vaccination is a key preventive strategy, multi-dose schedules pose cost and logistical challenges. This review assessed whether single-dose HPV vaccination offers protection comparable to multi-dose regimens. Following PRISMA guidelines, we searched PubMed, Cochrane, Scopus, and Google Scholar (2000-2025) for RCTs, cohort studies, and case-control studies comparing single-dose with two- or three-dose HPV vaccination. Outcomes included persistent HPV infection, high-grade cervical lesions (CIN2/3, HSIL), and immunogenicity. Random-effects models were used to calculate risk ratios (RRs), and heterogeneity was assessed with I². Twenty-six studies were included (10 RCTs, 16 observational), involving females aged 9-26 years from multiple countries. Sample sizes ranged from 200 to 590,083, with follow-up of 1-16 years. Single-dose vaccination showed >90% efficacy against persistent HPV16/18 infection. Compared with unvaccinated controls, the pooled estimate showed no statistically significant difference (RR 1.05, 95% CI 0.73-1.52). Compared with two-dose schedules, no statistically significant difference was observed (RR 0.72, 95% CI 0.40-1.32). Similarly, comparison with multiple-dose schedules showed no statistically significant difference (RR 0.93, 95% CI 0.60-1.44). Seropositivity remained high at 16 years (98.8-99.4%). Heterogeneity was substantial (I² 93.6-96.8%). Single-dose HPV vaccination provides substantial, durable protection comparable to multi-dose regimens in most settings. These findings support WHO’s recommendation and reinforce single-dose vaccination as a practical, cost-effective strategy to expand coverage and accelerate cervical cancer elimination in LMICs.
References
WHO. Feasibility of the WHO strategy to eliminate cervical cancer as a public health problem, lessons learned from the PRESCRIP-TEC project, 2024. Available at: https://www.knowledge-action-portal.com/en/content/feasibility-who-strategy-eliminate-cervical-cancer-public-health-problem-lessons-learned. Accessed on 30 March 2026.
WHO. Cervical cancer, 2022. Available at: https://www.who.int/health-topics/cervical-cancer#tab=tab_1. Accessed on 30 March 2026.
National Cancer Institute. Cervical cancer causes, risk factors, and prevention, 2024. Available at: https://www.cancer.gov/types/cervical/causes-risk-prevention. Accessed on 30 March 2026.
WHO. Global strategy to accelerate the elimination of cervical cancer as a public health problem. Geneva: World Health Organization, 2020. Available at: https://wkc.who.int/resources/publications/ i/item/9789240014107. Accessed on 30 March 2026.
UNICEF. Global leaders unite to accelerate cervical cancer elimination efforts, 2025. Available at: https://www.unicef.org/press-releases/global-leaders-unite-accelerate-cervical-cancer-elimination-efforts. Accessed on 30 March 2026.
National Cancer Institute. HPV and cancer, 2025. Available at: https://www.cancer.gov/about-cancer/causes-prevention/risk/infectious-agents/hpv-and-cancer. Accessed on 30 March 2026.
European Centre for Disease Prevention and Control. Guidance for the introduction of HPV vaccines in EU countries. Stockholm: ECDC, 2008. Available at: https://www.ecdc.europa.eu/sites/default/files/media/en/publications/Publications/0801_GUI_Introduction_of_HPV_Vaccines_in_EU.pdf. Accessed on 30 March 2026.
WHO. WHO updates recommendations on HPV vaccination schedule, 2022. Available at: https://www.who.int/news/item/20-12-2022-WHO-updates-recommendations-on-HPV-vaccination-schedule. Accessed on 30 March 2026.
Mayo Clinic. HPV vaccine: who needs it, how it works, 2023. Available at: https://www.mayoclinic. org/diseases-conditions/hpv-infection/in-depth/hpv-vaccine/art-20047292. Accessed on 30 March 2026.
Centers for Disease Control and Prevention. HPV vaccination, 2024. Available at: https://www.cdc.gov/hpv/vaccines/index.html. Accessed on 30 March 2026.
Shetty RS, Nadda A, Tambe M, Raut A, Goel K, Rao CR, et al. IAPSM’s position paper on the human papilloma virus (HPV) vaccine for adult immunization in India. Indian J Community Med. 2024;49(2):S125-31.
Johnson S. India gets its own HPV vaccine to stop 70,000 women dying of cervical cancer a year, 2024. Available at: https://www.theguardian.com/global-development/2024/mar/12/first-indian-made-hpv-vaccine-is-rolled-out. Accessed on 30 March 2026.
Toh ZQ, Russell FM, Garland SM, Mulholland EK, Patton G, Licciardi PV. Human papillomavirus vaccination after COVID-19. JNCI Cancer Spectr. 2021;5(2):pkab011.
Man I, Georges D, Sankaranarayanan R, Basu P, Baussano I. Building resilient cervical cancer prevention through gender-neutral HPV vaccination. eLife. 2023;12:e85735.
Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898.
NHLBI, NIH. Study quality assessment tools, 2021. Available at: https://www.nhlbi.nih.gov/health-topics/study-quality-assessment-tools. Accessed on 30 March 2026.
Barnabas RV, Brown ER, Onono M, Bukusi EA, Njoroge B, Winer RL, et al. Durability of single-dose HPV vaccination in young Kenyan women: randomized controlled trial 3-year results. Nat Med. 2023;29(12):3224-32.
Basu P, Malvi SG, Joshi S, Bhatla N, Muwonge R, Lucas E, et al. Vaccine efficacy against persistent human papillomavirus (HPV) 16/18 infection at 10 years after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre, prospective, cohort study. Lancet Oncol. 2021;22(11):1518-29.
Brotherton JML, Budd A, Rompotis C, Bartlett N, Malloy MJ, Andersen RL, et al. Is one dose of human papillomavirus vaccine as effective as three?: a national cohort analysis. Papillomavirus Res. 2019;8:100177.
Crowe E, Pandeya N, Brotherton JML, Dobson AJ, Kisely S, Lambert SB, et al. Effectiveness of quadrivalent human papillomavirus vaccine for the prevention of cervical abnormalities: case-control study nested within a population-based screening programme in Australia. BMJ. 2014;348:g1458.
Cuschieri K, Kavanagh K, Moore C, Bhatia R, Love J, Pollock KGJ. Impact of partial bivalent HPV vaccination on vaccine-type infection: a population-based analysis. Br J Cancer. 2016;114(11):1261-4.
Gertig DM, Brotherton JML, Budd AC, Drennan K, Chappell G, Saville AM. Impact of a population-based HPV vaccination program on cervical abnormalities: a data linkage study. BMC Med. 2013;11(1):227.
Joshi S, Anantharaman D, Muwonge R, Bhatla N, Panicker G, Butt J, et al. Evaluation of immune response to single dose of quadrivalent HPV vaccine at 10-year post-vaccination. Vaccine. 2023;41(1):236-45.
Kim J, Bell C, Sun M, Kliewer G, Xu L, McInerney M, et al. Effect of human papillomavirus vaccination on cervical cancer screening in Alberta. CMAJ. 2016;188(12):E281-8.
Kreimer AR, Rodriguez AC, Hildesheim A, Herrero R, Porras C, Schiffman M, et al. Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine. J Natl Cancer Inst. 2011;103(19):1444-51.
Kreimer AR, Sampson JN, Porras C, Schiller JT, Kemp TJ, Herrero R, et al. Evaluation of durability of a single dose of the bivalent HPV vaccine: the CVT trial. J Natl Cancer Inst. 2020;112(10):1038-46.
Rodriguez AM, Zeybek B, Vaughn M, Westra J, Kaul S, Montealegre JR, et al. Comparison of the long-term impact and clinical outcomes of fewer doses and standard doses of human papillomavirus vaccine in the United States: a database study. Cancer. 2020;126(8):1656-67.
Barnabas RV, Brown ER, Onono MA, Bukusi EA, Njoroge B, Winer RL, et al. Efficacy of single-dose human papillomavirus vaccination among young African women. NEJM Evid. 2022;1(5):EVIDoa2100056.
Safaeian M, Porras C, Pan Y, Kreimer A, Schiller JT, Gonzalez P, et al. Durable antibody responses following one dose of the bivalent human papillomavirus L1 virus-like particle vaccine in the Costa Rica Vaccine Trial. Cancer Prev Res. 2013;6(11):1242-50.
Safaeian M, Sampson JN, Pan Y, Porras C, Kemp TJ, Herrero R, et al. Durability of protection afforded by fewer doses of the HPV16/18 vaccine: the CVT trial. J Natl Cancer Inst. 2018;110(2):205-12.
Sankaranarayanan R, Prabhu PR, Pawlita M, Gheit T, Bhatla N, Muwonge R, et al. Immunogenicity and HPV infection after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre prospective cohort study. Lancet Oncol. 2016;17(1):67-77.
Verdoodt F, Dehlendorff C, Kjaer SK. Dose-related effectiveness of quadrivalent human papillomavirus vaccine against cervical intraepithelial neoplasia: a Danish nationwide cohort study. Clin Infect Dis. 2020;70(4):608-14.
Kavanagh K, Pollock KGJ, Potts A, Love J, Cuschieri K, Cubie H, et al. Introduction and sustained high coverage of the HPV bivalent vaccine leads to a reduction in prevalence of HPV 16/18 and closely related HPV types. Br J Cancer. 2014;110(11):2804-11.
Porras C, Safaeian M, Sampson JN, Pan Y, Kemp T, Herrero R, et al. HPV16/18 antibodies 16-years after single dose of bivalent HPV vaccination: Costa Rica HPV vaccine trial. JNCI Monogr. 2024;2024(67):329-36.
Shing JZ, Hu S, Herrero R, Hildesheim A, Porras C, Sampson J, et al. Precancerous cervical lesions caused by non-vaccine-preventable HPV types after vaccination with the bivalent AS04-adjuvanted HPV vaccine: an analysis of the long-term follow-up study from the randomised Costa Rica HPV Vaccine Trial. Lancet Oncol. 2022;23(7):940-9.
Watson-Jones D, Changalucha J, Whitworth H, Pinto L, Mutani P, Indangasi J, et al. Immunogenicity and safety of one-dose human papillomavirus vaccine compared with two or three doses in Tanzanian girls (DoRIS): an open-label, randomised, non-inferiority trial. Lancet Glob Health. 2022;10(10):e1473-84.
Brotherton JML, Budd A, Rompotis C, Bartlett N, Saville M, Drennan KT, et al. Effectiveness of less than three doses of quadrivalent human papillomavirus vaccine against cervical intraepithelial neoplasia when administered using a standard dose spacing schedule: observational cohort of young women in Australia. Papillomavirus Res. 2015;1:59-73.
Reyburn R, Tuivaga EJ, Ratu FT, Young S, Garland SM, Murray G, et al. A single dose of quadrivalent HPV vaccine is highly effective against HPV genotypes 16 and 18 detection in young pregnant women eight years following vaccination: a retrospective cohort study in Fiji. Lancet Reg Health West Pac. 2023;37:100798.
Batmunkh T, Dalmau MT, Munkhsaikhan M, Khorolsuren T, Namjil N, Surenjav U, et al. A single dose of quadrivalent human papillomavirus (HPV) vaccine is immunogenic and reduces HPV detection rates in young women in Mongolia, six years after vaccination. Vaccine. 2020;38(27):4316-24.
Markowitz LE, Liu G, Hariri S, Steinau M, Dunne EF, Unger ER, et al. Human papillomavirus vaccine effectiveness against HPV infection: evaluation of one, two, and three doses. J Infect Dis. 2020;221(6):910-8.
Toh ZQ, Russell FM, Reyburn R, Fong J, Tuivaga E, Ratu T, et al. Sustained antibody responses 6 years following 1, 2, or 3 doses of quadrivalent human papillomavirus (HPV) vaccine in adolescent Fijian girls, and subsequent responses to a single dose of bivalent HPV vaccine: a prospective cohort study. Clin Infect Dis. 2017;64(7):852-9.
Downloads
Published
How to Cite
Issue
Section
